Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Trastuzumab increases the incidence of cardiac events (CEs) in patients with breast cancer (BC). Dual blockade with pertuzumab (P) and trastuzumab (T) improves BC outcomes and is the standard of care for high-risk human epidermal growth factor receptor 2 (HER2)-positive early BC patients. We analyzed the cardiac safety of P and T in the phase III APHINITY trial.
PATIENTS AND METHODS: Left ventricular ejection fraction (LVEF) ≥ 55% was required at study entry. LVEF assessment was carried out every 3 months during treatment, every 6 months up to month 36, and yearly up to 10 years. Primary CE was defined as heart failure class III/IV and a significant decrease in LVEF (defined as ≥10% from baseline and to <50%), or cardiac death. Secondary CE was defined as a confirmed significant decrease in LVEF, or CEs confirmed by the cardiac advisory board.
RESULTS: The safety analysis population consisted of 4769 patients. With 74 months of median follow-up, CEs were observed in 159 patients (3.3%): 83 (3.5%) in P + T and 76 (3.2%) in T arms, respectively. Most CEs occurred during anti-HER2 therapy (123; 77.4%) and were asymptomatic or mildly symptomatic decreases in LVEF (133; 83.6%). There were two cardiac deaths in each arm (0.1%). Cardiac risk factors indicated were age > 65 years, body mass index ≥ 25 kg/m2, baseline LVEF between 55% and <60%, and use of an anthracycline-containing chemotherapy regimen. Acute recovery from a CE based on subsequent LVEF values was observed in 127/155 patients (81.9%).
CONCLUSIONS: Dual blockade with P + T does not increase the risk of CEs compared with T alone. The use of anthracycline-based chemotherapy increases the risk of a CE; hence, non-anthracycline chemotherapy may be considered, particularly in patients with cardiovascular risk factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ESMO open - 8(2023), 1 vom: 08. Feb., Seite 100772 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Azambuja, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Completed 12.03.2023 Date Revised 30.03.2023 published: Print-Electronic ClinicalTrials.gov: NCT01358877 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2022.100772 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351917276 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351917276 | ||
| 003 | DE-627 | ||
| 005 | 20231226052536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2022.100772 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351917276 | ||
| 035 | |a (NLM)36681013 | ||
| 035 | |a (PII)S2059-7029(22)00406-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Azambuja, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2023 | ||
| 500 | |a Date Revised 30.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01358877 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Trastuzumab increases the incidence of cardiac events (CEs) in patients with breast cancer (BC). Dual blockade with pertuzumab (P) and trastuzumab (T) improves BC outcomes and is the standard of care for high-risk human epidermal growth factor receptor 2 (HER2)-positive early BC patients. We analyzed the cardiac safety of P and T in the phase III APHINITY trial | ||
| 520 | |a PATIENTS AND METHODS: Left ventricular ejection fraction (LVEF) ≥ 55% was required at study entry. LVEF assessment was carried out every 3 months during treatment, every 6 months up to month 36, and yearly up to 10 years. Primary CE was defined as heart failure class III/IV and a significant decrease in LVEF (defined as ≥10% from baseline and to <50%), or cardiac death. Secondary CE was defined as a confirmed significant decrease in LVEF, or CEs confirmed by the cardiac advisory board | ||
| 520 | |a RESULTS: The safety analysis population consisted of 4769 patients. With 74 months of median follow-up, CEs were observed in 159 patients (3.3%): 83 (3.5%) in P + T and 76 (3.2%) in T arms, respectively. Most CEs occurred during anti-HER2 therapy (123; 77.4%) and were asymptomatic or mildly symptomatic decreases in LVEF (133; 83.6%). There were two cardiac deaths in each arm (0.1%). Cardiac risk factors indicated were age > 65 years, body mass index ≥ 25 kg/m2, baseline LVEF between 55% and <60%, and use of an anthracycline-containing chemotherapy regimen. Acute recovery from a CE based on subsequent LVEF values was observed in 127/155 patients (81.9%) | ||
| 520 | |a CONCLUSIONS: Dual blockade with P + T does not increase the risk of CEs compared with T alone. The use of anthracycline-based chemotherapy increases the risk of a CE; hence, non-anthracycline chemotherapy may be considered, particularly in patients with cardiovascular risk factors | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HER2-positive | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a cardiotoxicity | |
| 650 | 4 | |a pertuzumab | |
| 650 | 4 | |a trastuzumab | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a pertuzumab |2 NLM | |
| 650 | 7 | |a K16AIQ8CTM |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Agostinetto, E |e verfasserin |4 aut | |
| 700 | 1 | |a Procter, M |e verfasserin |4 aut | |
| 700 | 1 | |a Eiger, D |e verfasserin |4 aut | |
| 700 | 1 | |a Pondé, N |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaume, S |e verfasserin |4 aut | |
| 700 | 1 | |a Parlier, D |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Desmet, A |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, C |e verfasserin |4 aut | |
| 700 | 1 | |a Aguila, C |e verfasserin |4 aut | |
| 700 | 1 | |a Jerusalem, G |e verfasserin |4 aut | |
| 700 | 1 | |a Walshe, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Frank, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bines, J |e verfasserin |4 aut | |
| 700 | 1 | |a Loibl, S |e verfasserin |4 aut | |
| 700 | 1 | |a Piccart-Gebhart, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ewer, M S |e verfasserin |4 aut | |
| 700 | 1 | |a Dent, S |e verfasserin |4 aut | |
| 700 | 1 | |a Plummer, C |e verfasserin |4 aut | |
| 700 | 1 | |a Suter, T |e verfasserin |4 aut | |
| 700 | 0 | |a APHINITY Steering Committee and Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 8(2023), 1 vom: 08. Feb., Seite 100772 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:08 |g month:02 |g pages:100772 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2022.100772 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 08 |c 02 |h 100772 | ||